HE4 combined with CA125: favorable screening tool for ovarian cancer

Cancer statistics, 2012

Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2012 · 10.7K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

Richard G. Moore, D. Scott McMeekin, Amy Brown et al. · Gynecologic Oncology · 2008 · 866 citations

Medicine, Gynecology, Oncology +15

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

Usha Menon, Aleksandra Gentry‐Maharaj, Rachel Hallett et al. · The Lancet Oncology · 2009 · 834 citations · Full text

Medicine, Gynecology, Oncology +17

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Ingegerd Hellström, John Raycraft, Martha Hayden-Ledbetter et al. · PubMed · 2003 · 719 citations

Life Sciences, Molecular Biology, Oncology +17

Screening for ovarian cancer: a pilot randomised controlled trial

Ian Jacobs, Steven J. Skates, Nicola MacDonald et al. · The Lancet · 1999 · 575 citations

Medicine, Gynecology, Oncology +16